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Abstract 
Background: Few previous retrospective studies suggest that Plasmodium ovale wallikeri seems to have a longer 
latency period and produces deeper thrombocytopaenia than Plasmodium ovale curtisi. Prospective studies were war‑
ranted to better assess interspecies differences.
Methods: Patients with imported P. ovale spp. infection diagnosed by thick or thin film, rapid diagnostic test (RDT) or 
polymerase chain reaction (PCR) were recruited between March 2014 and May 2017. All were confirmed by DNA isola‑
tion and classified as P. o. curtisi or P. o. wallikeri using partial sequencing of the ssrRNA gene. Epidemiological, analyti‑
cal and clinical differences were analysed by statistical methods.
Results: A total of 79 samples (35 P. o. curtisi and 44 P. o. wallikeri) were correctly genotyped. Males predominate in 
wallikeri group (72.7%), whereas were 48.6% in curtisi group. Conversely, 74.3% of curtisi group were from patients of 
African ethnicity, whilst 52.3% of Caucasians were infected by P. o. wallikeri. After performing a multivariate analysis, 
more thrombocytopaenic patients (p = 0.022), a lower number of platelets (p = 0.015), a higher INR value (p = 0.041), 
and shorter latency in Caucasians (p = 0.034) were significantly seen in P. o. wallikeri. RDT sensitivity was 26.1% in P. o. 
curtisi and 42.4% in P. o. wallikeri. Nearly 20% of both species were diagnosed only by PCR. Total bilirubin over 3 mg/
dL was found in three wallikeri cases. Two patients with curtisi infection had haemoglobin under 7 g/dL, one of them 
also with icterus. A wallikeri patient suffered from haemophagocytosis. Chemoprophylaxis failed in 14.8% and 35% of 
curtisi and wallikeri patients, respectively. All treated patients with various anti‑malarials which included artesunate 
recovered. Diabetes mellitus was described in 5 patients (6.32%), 4 patients of wallikeri group and 1 curtisi.
Conclusions: Imported P. o. wallikeri infection may be more frequent in males and Caucasians. Malaria caused by P. 
o. wallikeri produces more thrombocytopaenia, a higher INR and shorter latency in Caucasians and suggests a more 
pathogenic species. Severe cases can be seen in both species. Chemoprophylaxis seems less effective in P. ovale spp. 
infection than in P. falciparum, but any anti‑malarial drug is effective as initial treatment. Diabetes mellitus could be a 
risk factor for P. ovale spp. infection.
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Antimalarials, Diabetes mellitus
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Background
Malaria remains a global health problem with more than 
212 million new cases in 2016 and 429,000 annual deaths 
worldwide, mostly driven by Plasmodium falciparum 
and Plasmodium vivax, to which most of the research 
resources are devoted [1].
Conversely, Plasmodium ovale spp. infection can be 
considered a neglected disease and little is known on its 
real incidence, geographic distribution, global disease 
burden or interactions with other Plasmodium species. 
The main problems for its study have been that it is fre-
quently misdiagnosed because of usual submicroscopic 
or low parasitaemia levels, low performance of malaria 
rapid diagnostic tests (RDT) [2] and a majority of mixed 
infections with other Plasmodium spp. [3].
Nowadays, polymerase chain reaction (PCR) tech-
niques have expanded the knowledge on P. ovale spp. 
epidemiology reporting infections in most of sub-Saha-
ran Africa, Southeast Asia, and the Indian subcontinent 
[4–6], but not in the Americas, with prevalences as high 
as 15% in zones of Nigeria or Papua New Guinea [3]. In 
addition, severe complications, such as acute respiratory 
distress syndrome (ADRS) [7], spleen rupture, severe 
anaemia, or death may occur in patients with P. ovale spp. 
malaria [8]. Lastly, the incidence of imported P. ovale spp. 
infection seems to be increasing among travellers return-
ing from West Africa [9–11], in whom chemoprophylaxis 
failed to work more frequently [12] compared to P. falci-
parum or P. vivax [13].
Since the study by Sutherland et  al. was published in 
2010, P. ovale is considered to comprise two genetically 
different subspecies, named P. ovale curtisi and P. ovale 
wallikeri that could have diverged 1–2 million years ago 
in their evolution [4]. They both are morphologically 
identical and cannot be differentiated by microscopy. 
Increasing information from different studies in endemic 
countries support that both subspecies co-circulate in 
Africa and Asia and are unable to recombine genetically 
[14–17].
Once established the genetic differences, the next ques-
tion was to find out if there were any other differences in 
epidemiology, microbiology or clinical features between 
both subspecies. Plasmodium o. curtisi and P. o. wallik-
eri do not seem to differ in parasitaemia levels [5, 9, 13] 
and the absence of Schüffner’s stippling may be a feature 
specific to P. o. wallikeri but only in 30% of blood sam-
ples [9]. Clinical differences between both species have 
not been clearly established, but P. o. wallikeri may have a 
shorter period of latency [13].
Recently, a multicentre, retrospective study in Spain 
was reported, comparing 21 imported P. o. curtisi and 
14 P. o. wallikeri infections confirmed by PCR and gene 
sequencing [5]. The only significant finding was more 
severe thrombocytopaenia among patients with P. o. 
wallikeri infection than among those with P. o. curtisi 
(p  =  0.031). However, non-significant trends showing 
shorter latency, lower albumin level, higher temperature 
and markers of more severe haemolysis were found in P. 
o. wallikeri group. Because of the retrospective design 
and small number of patients, larger, prospective studies 
were warranted to confirm these findings. Therefore, the 
results of a multicentre, prospective, comparative study 
of imported P. o. wallikeri and P. o. curtisi infections con-
ducted in several European countries during the period 
2014–2017 are presented below.
Methods
Study design
A prospective, observational, un-randomized, open-
label, multicentre study was performed at European 
hospitals of TropNet Europe, European Network for 
Tropical Medicine and Travel Health. Participants were 
recruited between March 2014 and May 2017. The study 
was approved by the University Hospital Príncipe de 
Asturias Ethical Board and at each site as needed. Writ-
ten informed consent was obtained from the participant 
or a legal representative before enrolment in the study. 
The trial was conducted in accord with the Declaration of 
Helsinki and Good Clinical Practice.
Microbiologic diagnosis
The initial diagnosis of imported P. ovale spp. infection 
was made up by thick and/or thin film and/or second 
generation RDT and/or PCR available in each hospital. 
Blood smears were stained by a standard technique with 
Giemsa solution for 30  min and were reviewed by an 
expert microbiologist. Parasite count was measured by 
determining the proportion of parasitized erythrocytes 
or the number of trophozoites per microlitre. Mixed 
infections with other Plasmodium species were excluded.
Laboratory samples
For cases tested positive, three drops (≈  50  μL) of full 
blood left after routine laboratory tests, were dotted on 
filter paper (Whatman™) and sent by regular mail to the 
Reference Malaria & Emerging Diseases Laboratory of 
the National Centre of Microbiology in Madrid. If DNA 
of P. ovale spp. had already been isolated, this was sent 
into a 1.5 mL screw cap tube with complete closure to the 
same Reference Laboratory.
Isolation of parasite DNA and molecular diagnosis 
confirmation
DNA isolation was performed using the QIAamp DNA 
blood mini kit  (QIAGEN®) from whole blood follow-
ing the manufacturer’s protocol. Molecular diagnosis 
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confirmation of P. ovale spp. was carried out by semi-
nested multiplex malaria PCR [18] which allows to dis-
tinguish the four more prevalent human malaria species.
Plasmodium ovale subspecies characterization 
and confirmation
Characterization of P. o. curtisi and P. o. wallikeri was 
performed by partial sequencing of the ssrRNA gene and 
ssrRNA amplification was performed by a nested PCR 
assay specific for Plasmodium genus. The first reaction 
included UNR (5′-GAC GGT ATC TGA TCG TCT TC-3′) 
and PLF (5′-AGT GTG TAT CCA ATC GAG TTTC-3′) 
primers [18]. The second PCR reaction incorporates the 
products of the first reaction along with NewPLFsh (5′-
CTA TCA GCT TTT GAT GTT AG-3′) and NewRevsh (5′-
CCT TAA CTT TCG TTC TTG -3′) primers. Infection with 
different malaria species yields products of different sizes 
between 710 and 740 bp.
The PCR mixture in both reactions consisted of 75 mM 
TrisHCl (pH 9.0), 2  mM  MgCl2, 50  mM KCl, 20  mM 
 (NH4)2SO4, 200  μM of dNTP, 0.075  µM of each prim-
ers, 1.25 units of Taq DNA polymerase (Biotools B&M 
Labs., S.A., Madrid, Spain), and 5 μL of DNA, extracted 
by QIAgen kit, was used as template in a reaction vol-
ume of 50 μL. For the second reaction mixture, 2 µL of 
the PCR product of the first reaction was used as tem-
plate. For both reactions, a  GeneAmp® PCR System 2700 
thermal cycler (Applied Biosystems Laboratory) was 
used, beginning with 7  min at 94  °C, followed by (first-
round) 40 cycles of 20 s at 94 °C, 20 s at 62 °C, and 30 s at 
72 °C, or (second-round) 35 cycles of 20 s at 94 °C, 20 s at 
53 °C, and 20 s at 72 °C. The final cycle was followed by 
an extension time of 10 min at 72 °C.
The amplified products were purified using Illustra 
DNA and Gel Band Purification Kit (General Electric 
Healthcare) and sequenced with the Big Dye Termina-
tor v3.1 Cycle Sequencing in an ABI  PRISM® 3700 DNA 
Analyzer. All amplified products were sequenced in both 
directions twice.
In order to confirm P. ovale subtyping, a nested PCR 
amplification plus sequencing targeting cytochrome b 
was performed in three samples of each group.
Data collection
An anonymized database was designed to input all the 
medical information and laboratory registries in a pro-
spective way. Data collected included gender, age, eth-
nicity, underlying diseases, type of patient, dates and 
purpose of travel, countries visited, malaria chemopro-
phylaxis, date of admission and diagnosis, presenting 
clinical signs or symptoms and complications of severe 
malaria according to criteria of the World Health Organi-
zation (WHO) [19] where no threshold of parasitaemia 
for P. ovale spp. was established. The closest possible 
date of inoculation was defined as the day of departure 
from a malaria endemic area. The time between date of 
arrival and onset of illness or diagnoses was calculated 
once asymptomatic patients were excluded. Patients were 
classified as an early immigrant if they had stayed in a 
country without malaria for less than a year prior to diag-
nosis. An immigrant was a VFR (visiting friends and rela-
tives) if travelled to a country endemic of malaria after a 
year of stay in a non-malarial area, and VFR traveller if 
visited his/her first-degree relative’s country of birth hav-
ing been born in a non-malaria endemic country. Recent 
Plasmodium infection was defined as probable or defi-
nite malaria infection in the previous 12 months before P. 
ovale spp. diagnosis.
Laboratory results included microbiological data with 
parasitaemia count, full blood count with white blood 
cells, haemoglobin and platelets, values of glucose, cre-
atinine, albumin, transaminases, lactate dehydrogenase 
(LDH), total bilirubin (tBR) in plasma, the coagula-
tion parameters activated partial thromboplastin time 
(APTT) and international normalized ratio (INR), glu-
cose-6-phosphate dehydrogenase (G6PDH) activity in 
red blood cells, as well as serological studies of infection 
with human immunodeficiency virus (HIV), hepatitis 
B (HBV) and hepatitis C (HCV). Thrombocytopaenia 
was defined as a platelet count under 150,000/µL. Treat-
ments, clinical and microbiological evolution and dura-
tion of hospital stay of those admitted were recorded. 
Treatments were performed following the guidelines 
of each country and health centre without a common 
recommendation.
Statistical analysis
Differences of proportions were evaluated by the Chi-
squared-test if less than 20% of cells had five or less 
expected values. If more than 20% of cells had five or less 
expected values we used the Fisher’s exact test for cat-
egorical variables. Differences of means between groups 
were calculated by the Student’s t-test for independent 
samples if the normal distribution could be assumed. In 
the Student’s t test for independent samples, the Levene’s 
test for homogeneity of variances was used. If normal dis-
tribution was not valid, the non-parametric Mann–Whit-
ney U-test was performed. To test for normality, either 
the Shapiro–Wilks for small samples or the Kolmogorov–
Smirnov with Lilliefors’ correction for large samples were 
used. Values are reported as number of patients and per-
centage or, for non-parametric distributions, as median 
and interquartile range (IQR). A multivariate linear 
regression analysis was performed for continuous vari-
ables and multivariate logistic regression for categorical 
variables to confirm if real differences were found when 
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non-homogenous population between both groups were 
identified. A two-sided p value of 0.05 or less was consid-
ered to indicate statistical significance. Statistical analysis 
was performed using the SPSS version 21 (SPSS Inc, Chi-
cago, IL, USA).
Results
During the period of the study, a total of 96 blood sam-
ples from 29 hospitals were sent to the reference labo-
ratory. Of them, 13 were excluded because of mixed 
infections (11 with P. falciparum, 1 with P. vivax and 1 
with Plasmodium malariae), 2 samples did not get ampli-
fied and data from another 2 were not obtained. At the 
end, 79 correctly genotyped and with complete patient 
information were included for statistic analysis. Of them, 
35 were identified as P. o. curtisi and 44 as P. o. wallikeri.
Table 1 presents demographic and epidemiological data 
from both groups. A significant difference in the distribu-
tion of gender, ethnicity and type of patients was shown. 
Males clearly predominate in wallikeri group whereas 
gender distribution was more evenly matched in the 
curtisi group. Conversely, on ethnicity, African patients 
were 74.3% of curtisi group. This ethnic distribution is 
reflected in the type of patient with a majority of VFR 
and recent immigrants in the P. o. curtisi infection versus 
a larger number of displaced for working or cooperation 
in the other species. The remaining epidemiological data 
did not differ including country of infection, duration of 
travel, chemoprophylaxis, latency time, time until diag-
noses, recent Plasmodium infection or underlying dis-
eases. There is a wide range of 21 countries as the place of 
infection, most of them in West Africa.
Microbiological and laboratory information is reported 
in Table 2. Several analytical parameters showed statisti-
cally significant differences such as total leukocyte and 
platelet count, number of thrombocytopaenic patients, 
haemoglobin, creatinine, LDH or INR values. Even after 
the multivariate study was performed, eliminating the 
confounding factor of ethnicity, the number of plate-
lets, thrombocytopaenic patients and INR remained sig-
nificant (Table 3). Latency time was also included in the 
multivariate analysis because of the significant difference 
found in a previous report [13]. A statistically shorter 
latency period also appeared, but only in Caucasians 
patients with P. o. wallikeri compared to those in the 
curtisi group. On the other hand, no difference in parasi-
tological data including submicroscopic infection, parasi-
taemia or sensitivity of the common antigen of RDT was 
seen.
In respect of the clinical manifestations and time of 
hospitalization no differences were found in (Table  4). 
Treatments were widely different according to the pro-
tocols of each centre. Primaquine was supplied to most 
patients in both groups and only three patients showed 
G6PDH deficiency that contraindicated this treatment. 
Five patients showed analytical criteria for severe malaria 
and another one a rare and severe complication (hae-
mophagocytosis). Outcome in nearly all cases was good, 
although two patients did not receive any anti-malarial 
treatment due to loss of follow-up.
Discussion
This is the largest prospective study to date on the two 
species of infection by imported P. ovale trying to over-
come recruitment difficulties and limitations of previous 
retrospective studies.
On the results obtained, significant differences were 
found in the epidemiological characteristics of sex, eth-
nicity and type of patients between both groups. Ethnic 
differences may be the main confounding factor since 
there is a greater probability that African patients retain 
some semi-immunity against P. ovale spp. infection 
(excluding VFR travellers), which would generally result 
in less clinical and analytical involvement [20]. On the 
other hand, the difference in sex distribution and type of 
patients seems to be clearly related to the ethnic origin 
since in a subgroup analysis, 16 out of 18 (89%) of the 
patients with P. o. wallikeri who travelled by international 
cooperation were male and Caucasians, which would bias 
the characteristics of this group.
This distribution could be a result of chance alone or 
due to the fact that actually Caucasians patients are more 
susceptible to infection by wallikeri parasites. However, 
a previous retrospective study did not show these differ-
ences in sex, ethnicity or type of patient [5] and the few 
studies of imported ovale malaria reporting a significant 
number of patients showed either equality of sexes (but 
did not report on ethnicity) [13] or they were nearly all 
Chinese men who worked in African countries [10].
When performing the multivariate study adjusted by 
ethnicity to reduce this confounding factor, the number 
of patients with thrombocytopaenia and two of the ana-
lytical alterations remained significant. Thrombocyto-
paenia was more pronounced in P. o. wallikeri and INR 
values were higher in the wallikeri group. The compara-
tion of the rest of analysis variables were not finally sig-
nificant, over all those that indicate a greater degree of 
haemolysis, such as LDH, tBR or haemoglobin level.
In the case of thrombocytopaenia, these results con-
firm the main finding of a previous retrospective study 
where the only difference was more severe thrombocyto-
paenia in P. o. wallikeri infection [5]. Thrombocytopaenia 
is a common finding in patients with malaria of all Plas-
modium species ranging from 24 to 94% of indicence, 
although spontaneous haemorrhages are infrequent and 
limited to very severe cases [21]. Also it is of note that 
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 Male 17 (48.6) 32 (72.7)
 Female 18 (51.4) 12 (27.3)
Age, median years (IQR) 35 (23.0–53.0) 38.5 (22.2–52.7) 0.529
Ethnicity 0.017
 African 26 (74.3) 21 (47.7)
 Caucasian 9 (25.7) 23 (52.3)
Type of patient 0.034
 Early immigrant 11 (31.4) 4 (9.0)
 Visiting friends and relatives 14 (40.0) 17 (38.6)
 VFR traveller 1 (2.9)
 Tourism 3 (6.8)
 Work/cooperation 7 (20.0) 17 (38.6)
 Expatriate, long‑term stay 2 (5.7) 3 (6.8)
Country of infection 0.097
 Equatorial Guinea 14 (40.0) 11 (25.0)
 Nigeria 5 (14.3) 6 (13.6)
 Cameroon 1 (2.9) 11 (25.0)
 Togo 1 (2.9) 1 (2.3)
 Liberia 2 (5.7)
 Tanzania 1 (2.3)
 Guinea‑Conakry 1 (2.9) 1 (2.3)
 Ivory Coast 3 (8.6) 2 (4.5)
 Mozambique 1 (2.9) 2 (4.5)
 Congo 1 (2.9) 1 (2.3)
 Congo Democratic Republic 1 (2.3)
 Uganda 2 (5.7)
 Chad 2 (4.5)
 Ghana 1 (2.9) 1 (2.3)
 Sierra Leone 1 (2.3)
 Sudan 1 (2.9)
 Burundi 1 (2.9)
 Angola 1 (2.3)
 Mali 1 (2.3)
 Guinea‑Bissau 1 (2.3)
 Madagascar 1 (2.9)
Duration of travel, median days (IQR) 101 (21.0–240.0) 38.5 (26.7–157.5) 0.547
Chemoprophylaxis 0.078
 No prophylaxis 14 (60.8) 24 (60.0)
 Incomplete 5 (21.7) 2 (5.0)
 Complete 4 (17.4) 14 (35.0)
Time from arrival to onset of symptoms, median days (IQR) 34.0 (13.0–181.25) 30.5 (10.0–86.25) 0.171
Time from onset of symptoms to diagnoses, median days (IQR) 3 (0.0–10.0) 3.5 (0.7–8.0) 0.772
Recent Plasmodium infection 16 (51.6) 15 (40.5) 0.361
Other underlying conditions 1
 G6PDH deficit 1/30 (3.3) 2/37 (5.4)
 Diabetes mellitus 1 (2.9) 4 (9.0) 0.3756
 Drepanocytosis 1 (2.9) 1 (2.3)
 Pregnancy 1 (2.9) 0
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thrombocytopaenia seems to be a very common finding 
in P. ovale spp. infection. Of the 79 patients analysed, 53 
(67%) had under 150,000 platelets/µL, which corresponds 
to our previous series findings of 66.6% in 16 imported 
ovale infection patients [22] and a retrospective study 
where 26 out of 35 patients (75.3%) suffered from throm-
bocytopaenia [5]. Only one patient in each group showed 
under 50,000 platelets/µL again without any haemor-
rhagic feature.
The pathogenesis of thrombocytopaenia in malaria 
is not fully understood but is accepted that encom-
passes several different mechanisms that lead to 
increased platelet destruction or consumption, such as 
increased attachment to endothelium and adherence 
to Von Willebrand factor, clumping and agglutination 
of infected and uninfected erythrocytes, consumption 
into the coagulation process and haemolysis, increased 
diffuse platelet sequestration, decreased nitric oxide 
Values are no. (%) or no. positive/total no. (%) and median (interquartile range). Italicface indicates significance







 Chronic kidney disease 0 1 (2.3)
 Splenectomy 1 (2.9) 0
 Hepatitis B virus 0 3 (6.8)
 Hepatitis C virus 1 (2.9) 0
 HIV 3 (8.6) 1 (2.3)
Table 2 Microbiological and analytical characteristics
Values are no. (%) or no. positive/total no. (%) and median (interquartile range). Italicface indicates significance
IQR interquartile range, PCR polymerase chain reaction, WBC white blood cells, LDH lactate dehydrogenase, AST aspartate aminotransferase, ALT alanine 






Positive thick smear 28/34 (82.4) 36/42 (85.7) 0.689
Only PCR positive 5 (18.5) 6 (19.4) 1
Parasitaemia, median × µL (IQR) 2550 (647.5–11,677.5) 946 (600–4450) 0.441
Parasitaemia index 0.275
 Very low ≤ 0.01% 3/22 (13.6) 7/28 (25.0)
 Low 0.02–0.1% 8/22 (36.4) 13/28 (46.4)
 Medium > 0.1% 11/22 (50.0) 8/28 (28.6)
Rapid diagnostic test
 Common antigen positive 6/23 (26.1) 14/33 (42.4) 0.209
 P. falciparum antigen positive 0/23 (0.0) 3/33 (9.1) 0.502
Total WBC count, median cells/µL (IQR) 5600 (4600–6270) 4460 (3827–6015) 0.049
Haemoglobin level, median g/dL (IQR) 12.1 (10.1–13.5) 13.2 (11.5–14.1) 0.032
Platelet count, median cells/µL (IQR) 130,000 (81,000–281,000) 105,500 (69,000–141,500) 0.039
Platelet count < 150,000 cells/µL 19 (54.3) 34 (79.1) 0.016
Albumin level, median g/dL (IQR) 3.60 (3.20–4.00) 3.38 (3.02–3.73) 0.139
Creatinine level, median mg/dL (IQR) 0.79 (0.59–1.00) 0.95 (0.75–1.10) 0.030
LDH level, median value × IU/L (IQR) 267.0 (221.2–367.2) 370.0 (256.0–508.7) 0.028
AST level, median IU/L (IQR) 27.00 (20.00–32.50) 25.50 (19.90–43.75) 0.691
ALT level, median IU/L (IQR) 30.00 (18.00–43.20) 24.00 (18.00–48.00) 0.648
Total bilirubin level, median mg/dL (IQR) 0.83 (0.60–1.35) 1.22 (0.70–1.80) 0.086
INR, median (IQR) 1.08 (0.96–1.17) 1.12 (1.10–1.20) 0.019
APTT, median (IQR) 29.50 (25.10–37.07) 30.65 (26.27–32.97) 0.762
Glucose, median mg/dL (IQR) 91.5 (83.0–103.7) 97.0 (82.0–113.0) 0.468
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bioavailability, and immune complexes-mediated 
destruction [23].
Although thrombocytopaenia is not among the severity 
criteria of the WHO, evidence is accumulating that it can 
predict an adverse outcome, which seems to be driven 
by a greater severity of illness in P. falciparum or P. vivax 
[21, 24] and severe thrombocytopaenia can identify an 
increased risk of death from falciparum or vivax malaria 
[25]. Therefore, in the case of P. o. wallikeri it could indi-
cate a greater intrinsic pathogenicity of this species com-
pared to P. o. curtisi, although without evidence of any 
major significantly worse clinical criteria of severity.
Regarding the other significant finding of this study, 
the higher INR elevation in P. o. wallikeri compared to 
P. o. curtisi, this increase was always mild and in no case 
exceeded the value of 1.54 nor was related to any bleed-
ing. On the other hand, the APTT values were similar 
in both groups. No other coagulation factors, fibrino-
gen levels, fibrin degradation products or d-dimer were 
measured that could argue in favour of a significant coag-
ulation disorder.
It is well known that P. falciparum malaria is associ-
ated with significant coagulation activation. The increase 
in INR or its equivalent, prolongation of prothrombin 
time, is produced by the activation of the extrinsic path-
way of the coagulation cascade and can lead to dissemi-
nated intravascular coagulation in the most severe cases 
of malaria. Plasmodium falciparum seems to trigger 
coagulation activation through multiple different path-
ways although the mechanisms involved are not well 
understood [26]. Much less information on coagulation 
is available in P. ovale spp. infection. In the case of INR, 
the finding of this study might support the hypothesis of 
a more pathogenic wallikeri parasite, but does not seem 
to pose a significant clinical difference or severity.
In the initial analysis, no differences were found in the 
latency period, but when the multivariate analysis was 
performed a significant shorter time appeared in P. o. 
wallikeri compared to P. o. curtisi infection, but only in 
Caucasians patients. This difference is more significant 
since only one of the seven Caucasians patients who suf-
fered infection by P. o. curtisi had taken adequate proph-
ylaxis versus 11 out of 22 (50%) of the wallikeri group, 
which should have lengthened their latency. The retro-
spective study by Nolder et al. in the UK also found sig-
nificant shorter latency period in wallikeri cases but did 
not report the ethnicity or patient characteristics [13]. 
On the contrary, another study in Chinese people (ethni-
cally homogeneous but with unknown previous exposure 
to malaria or chemoprophylaxis use) encompassing 109 
P. o. curtisi and P. o. wallikeri [10] imported from Africa, 
did not find any difference in latency. In a previous ret-
rospective study, only a trend to shorter wallikeri latency 
was found (p = 0.07) [5].
These results of different latency times in only Cau-
casians patients suggest a strong influence of the previ-
ous partial immunity to malaria in the time of symptoms 
of P. ovale spp. infection. Finally, note that in both spe-
cies latencies greater than 1  year have been found as 
described previously [11].
A complete chemoprophylaxis was reported in 22.8% 
of ovale spp. infections and up to 35% in P. o. wallikeri, a 
high percentage if compared with data from large series 
of imported malaria as in USA 2014, where only 7.8% 
of travellers correctly took prophylaxis [11]. If analysed 
by Plasmodium species, these results are similar to the 
Table 3 Multivariate linear regression and  multivariate logistic regression analysis related to  ethnicity of  parameters 
with significant differences in univariate analysis and latency time
Values show the relationship of P. o. wallikeri respect to P. o. curtisi. Italicface indicates significance
WBC white blood cells, LDH lactate dehydrogenase, INR international normalized ratio
Regression coefficients 95% confidence interval p
Total WBC count, ×109 cells/L − 850.884 − 1931.456 to 229.689 0.121
Haemoglobin level, g/dL − 0.903 − 0.085 to 1.891 0.073
Platelet count cells/µL − 39,707.641 − 71,351.311 to − 8063.972 0.015
Creatinine level, mg/dL 0.095 − 0.024 to 0.215 0.117
LDH level, IU/L 12.537 − 160.156 to 185.230 0.885
INR 0.077 0.003–0.151 0.041
Time from arrival to onset of symptoms, days
 African patients − 41.108 − 127.135 to 44.920 0.344
 Caucasian patients − 75.001 − 144.040 to − 5.962 0.034
Odds ratio 95% confidence interval p
Platelet count < 150,000 cells/µL 0.314 0.117–0.847 0.022
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study by Nolder et al. which stated that the proportion 
of ovale malaria which occurred in patients reporting 
chemoprophylaxis use (33%) was significantly higher 
than for P. falciparum (6.4%) and P. vivax (23.7%) [13]. 
Also, in a USA and Israel study, up to 73% of imported 
P. ovale spp. used an effective prophylaxis [27]. Moreo-
ver, in a recent Spanish study considering only the sub-
group of travellers with P. ovale/P. vivax malaria, these 
patients had also taken chemoprophylaxis significantly 
more frequently than those with non-P. ovale/P. vivax 
malaria (35.5% vs. 2.7%) [28]. These results reinforce 
the idea that current prophylaxis does not adequately 
act on P. ovale spp. infection, since it is ineffective 
against its hypnozoites and, therefore, does not prevent 
a delayed primary attack or true relapses from occur-
ring when there is no prophylactic medication in blood.
Although the information cannot be completely relia-
ble, over 40% of patients reported an episode of malaria 
in the previous 12  months. This could have been a 
primary infection by P. ovale, another ovale relapse, 
a mixed infection with other Plasmodium or simply 
a non-ovale malaria unrelated to the current episode. 
Since it is not feasible to obtain a previous diagnostic 
sample, it is impossible to know if the current episode 
Table 4 Clinical and therapeutic characteristics
Values are no. (%) or no. positive/total no. (%) and median (interquartile range)
IQR interquartile range
a This patient had drepanocytosis






Asymptomatic 2 (5.7) 2 (4.5) 1
Fever 32 (91.4) 39 (88.6) 1
Headache 17 (48.6) 29 (65.9) 0.121
Nausea 9 (25.7) 11 (25.0) 0.942
Arthralgia 10 (28.6) 15 (34.1) 0.600
Myalgia 17 (48.6) 18 (40.9) 0.496
Vomitus 4 (11.4) 12 (26.3) 0.082
Abdominal pain 5 (14.3) 3 (6.8) 0.460
Diarrhea 4 (11.4) 5 (11.4) 1
Other (cough, dyspnea, chest pain, dizziness) 9 (25.7) 10 (22.7) 0.758
Duration of hospitalization, median days (IQR) 4 (2.0–6.0) 3 (3.0–6.0) 0.713
Treatment 0.826
 Chloroquine 17 (48.6) 18 (40.9)
 Atovaquone/proguanil 12 (34.2) 11 (25.0)
 Quinine + doxycycline 2 (4.5)
 Atovaquone/proguanil + chloroquine 1 (2.9) 1 (2.3)
 Artesunate + artemether–lumefantrine 1 (2.9)
 Dihidroartemisinin–piperaquine 3 (8.6) 7 (15.9)
 Artemether–lumefantrine 1 (2.3)
 Artesunate + chloroquine 1 (2.3)
 Artesunate + atovaquone/proguanil 1 (2.9)
 Artesunate 1 (2.3)
 Lost to follow up, no treatment 2 (4.5)
Primaquine 25 (71.4) 34 (81.0) 0.325
Severe malaria and complications 1
 Total bilirubin > 3 mg/dL and haemoglobin < 7 g/dL 1 (2.9)a
 Total bilirubin > 3 mg/dL 3 (6.8)b
 Haemoglobin < 7 g/dL 1 (2.9)
 Haemophagocytosis 1 (2.3)
Exitus 0 0 1
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represented a primary infection or a relapse by P. ovale. 
Primary infection could only be diagnosed in the cases 
of first malarial episode and very short latency period.
Regarding the underlaying conditions, it is worth 
focusing on diabetes mellitus and drepanocytosis. The 
prevalence of diabetes mellitus is increasing worldwide, 
especially in low income countries, as are found in sub-
Saharan Africa [29]. The number of diabetics in this 
study is as high as 6.32% (5/79) in a population with a low 
average age, especially in wallikeri group. In a retrospec-
tive curtisi–wallikeri study up to 8.5% of patients suffered 
from diabetes [5] and in a previous study of imported 
P. ovale infection 3 out of 16 patients (18.7% with mean 
age 30.6 years) were also diabetics [22]. A recent Swed-
ish study, reported diabetes in 3.5% of 937 patients with 
imported P. falciparum and 2.5% in 398 imported malaria 
in a Spanish Tropical Medicine Centre [30]. In a series of 
229 P. falciparum infections from 2006 to 2015 in Hos-
pital Universitario Príncipe de Asturias (HUPA), 2.6% 
were diabetics (unpublished data). As diabetes is a known 
risk factor for malaria due to P. falciparum in endemic 
areas [31], the higher prevalence of this chronic disease 
in P. ovale studies might indicate that would also be a risk 
factor, and deserves further investigation to confirm this 
finding.
In endemic areas, carrying the sickle cell trait repre-
sents a risk factor for infection by P. ovale spp. [20] and 
a partial protective factor against severe P. falciparum 
infection. In this study, 2 out of 47 African patients (4.2%) 
had drepanocytosis. Moreover, in the previous com-
parative retrospective study, 8.3% (2 out of 24) showed 
drepanocytosis and up to 23% (3/13) in the series of 16 
imported P. ovale spp. [22]. Gathering African patients 
from the three studies (7/84) and comparing to 1.35% of 
patients in 221 African people with imported P. falcipa-
rum in HUPA during the period 2006–2015 (unpublished 
data) significant difference can be found (p < 0.005) that 
would support the results of the study conducted in 
endemic area.
As in previous studies, no differences were detected 
in parasitaemias between both groups [6, 9, 32]. Most of 
them had low parasite counts clearly below 1%, making 
it even more difficult to find statistically real differences. 
Surprisingly, two patients reached 2% parasitaemia, a 
Caucasian traveller without any immunity to malaria and 
a child with drepanocytosis and intense anaemia that 
enhanced the proportion of infected red blood cells. Such 
high parasitaemia has been rarely described, sometimes 
linked to serious complications such as spleen rupture 
[33]. Finally, the absence of Schüffner’s stippling in blood 
smear, which has been described as a possible feature 
specific to P. o. wallikeri, was not studied.
There was also no difference in the sensitivity of RDTs, 
which was low as described in the literature [2] without 
exceeding 45% in either group. Almost 20% of the cases 
in both groups were diagnosed only by PCR, as RDT and/
or thick blood smears were negative. In endemic areas 
this percentage is much higher, especially in asympto-
matic patients [3]. Therefore, if the clinical and epidemio-
logical suspicion is high, it would be convenient to repeat 
the diagnostic tests and request molecular PCR tech-
niques not to miss P. ovale spp. diagnosis.
This study confirms that this infection can cause 
malaria with severity criteria or complications, in this 
case 7.6% of all patients with no differences between both 
species. In series of imported malaria by P. falciparum the 
rate of severe cases was around 2–17% [11, 34], but with a 
much higher incidence of life-threatening complications, 
such as ADRS, severe anaemia or cerebral malaria than 
described in P. ovale spp. infection [8]. A rare case of hae-
mophagocytosis was included that had been described 
only in P. falciparum and P. vivax infection [35], but not 
in P. ovale spp. Analysing the six patients with severe 
malaria or complications, two had drepanocytosis (which 
also produces anaemia) and one was diabetic, which 
might indicate the possible importance of these risk fac-
tors in the severity of P. ovale spp. infection.
In cases of malaria with tBR >  3  mg/dL, the WHO 
severity criteria add parasitaemia levels above 100,000/
µL in P. falciparum and > 20,000/µL in P. vivax and Plas-
modium knowlesi, but is not known in the case of P. ovale 
spp. In this study, all four cases with tBR > 3 mg/dL had 
parasitaemias over 4000/µL. In addition, four patients 
received parenteral artesunate, two of them with tBR 
>  3  mg/dL and one with unusually high parasitaemias 
of 2%. It is described that host response may reach full 
strength at lower parasitaemia in P. vivax and P. ovale 
spp. infection than in P. falciparum [36] so, perhaps it 
would be also convenient to establish a threshold of para-
sitaemia with jaundice and hyperparasitaemia in P. ovale 
spp. in the face of treatment decisions and outcome.
The treatments were very varied, including artemisinins 
alone or in combination, atovaquone/proguanil, chloro-
quine or quinine-doxycycline, all with good initial clinical 
evolution, which is compatible with the sensitivity of P. 
ovale spp. described for multiple antimalarials [8]. Over 
70% of them received primaquine with good tolerance, 
although there was no long-term follow-up recorded to 
assess episodes of relapse or late recrudescence.
The prospective study design has minimized some of 
the limitations of the previous retrospective study but 
some of them still remain. First, although it is one of the 
largest studies carried out worldwide, the number of 
patients may still lack sufficient statistical power to show 
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other differences between infections with both P. ovale 
species. Second, only strains of P. ovale from Africa, and 
patients from Africa and Europe were analysed; a study 
of infections and patients from Asia, Oceania or other 
places might show different results. Third, the behaviour 
of these species in endemic countries may be different 
but it would be difficult to gather a significant number of 
patients with P. ovale spp. monoinfection due to the high 
prevalence of mixed Plasmodium infections and malaria 
reinfections. Fourth, the date of infection is a minimal 
approximate and it is virtually impossible to distinguish 
a primary infection from a relapse. Last, a mix of eth-
nicities, non-immune and semi-immune patients led to 
heterogeneous study groups, although the multivariate 
statistical study has reduced this bias.
Conclusions
In this study, imported P. o. wallikeri infection was more 
frequent in males and Caucasian patients than in P. o. 
curtisi group. Malaria caused by P. o. wallikeri produced 
more thrombocytopenic patients, more marked throm-
bocytopaenia and a higher INR than P. ovale curtisi, 
although without other clinical or severity differences. 
Plasmodium o. wallikeri malaria had shorter latency, but 
only in Caucasian patients. These findings suggest that 
wallikeri species might be somewhat more pathogenic 
than P. ovale curtisi. Some cases with severity criteria 
were seen in both species and required treatment with 
intravenous artesunate. The clinical evolution with any 
anti-malarial drug was usually good, however, chemo-
prophylaxis seemed less effective in P. ovale spp. infec-
tion than in the case of P. falciparum. Diabetes mellitus 
might also be a risk factor for P. ovale spp. infection such 
as drepanocytosis. Current RDT was shown to have low 
diagnostic sensitivity in both species and PCR was essen-
tial for diagnosis in a significant percentage of cases.
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